Jump to Navigation

Facebook Connect

User login

nla






Overview


Join the National Lipid Association in New Orleans for the 2016 Scientific Sessions, May 19-22, 2016 at the New Orleans Hyatt Regency, hosted by the Southwest Lipid Association. 

You won't want to miss this one-of-a-kind educational experience! Stay informed on the latest scientific and clinical developments in lipidology through a wide-ranging and comprehensive agenda.

Earn more CME/CE Credits when you attend one of three pre-conference courses on May 18-19.

  • NEWLY ADDED: Translational Science of the LDL Receptor: an NLA Core Curriculum Intensive Program
  • Lipid Academy
  • Masters in Lipidology

For more information about the pre-conference courses, click here.

Download Program Now

Keynote Speakers

Agenda


Thursday, May 19, 2016

Session I: The Impact of Genetics in Lipidology
3:45- 4:00 PM
NLA Presidents Welcome
Carl E. Orringer, MD, FNLA
4:00- 4:30 PM
Human genetics and CV Risk Assessment
Nathan O. Stitziel, MD, PhD
4:30- 5:00 PM
Human Genetics Impact on Clinical Practice in Lipidology
Muredach P. Reilly, MBBCH
5:00- 5:30 PM
Gene Therapy
Marina Cuchel, MD, PhD
5:30- 6:00 PM
ARS Questions/ Panel Session Q&A
6:00- 7:00 PM
Welcome Reception in Exhibit Hall
7:00- 9:00 PM
CME Dinner Symposium- Unpeeling the Science and Management of Triglycerides
6:45- 9:15 PM
CME/CE Satellite Symposium: Unpeeling the Science and Management of Triglycerides
Sergio Fazio, MD, PhD
6:45- 9:15 PM
CME/CE Satellite Symposium: Unpeeling the Science and Management of Triglycerides
R. Preston Mason, PhD
6:45- 9:15 PM
CME/CE Satellite Symposium: Unpeeling the Science and Management of Triglycerides
Michael Miller, MD, FACC

Friday, May 20, 2016

6:45- 8:00 AM
Breakfast in Exhibit Hall
7:05- 7:50 AM
Late Breaking Presentations
8:00- 8:15 AM
PLA & SELA Chapter Business Meetings
8:15- 8:25 AM
Morning Notes and ARS Questions
8:25- 9:25 AM
Keynote Lecture: Apo C3 , Risk factor, Pathophysiology and Target
Anne Tybjærg-Hansen, MD, DMSc
9:25- 10:25 AM
Break in Exhibit Hall & Poster Hall Q&A Session
9:30- 10:20 AM
Non-CME Expert Theater
Session II: Focus on Lipoprotein(a)
10:25- 10:30 AM
ARS Questions
10:30- 10:55 AM
Lipoprotein(a) as a Cause of Cardiovascular Disease
Børge G. Nordestgaard, MD, DMSc
10:55- 11:20 AM
Pathophysiology of Lipoprotein(a)- Atherosclerosis & Thrombosis
Sergio Fazio, MD, PhD, FNLA
11:20- 11:45 AM
Drugs in Development to Treat Lp(a): Risk Reduction vs. Lowering a number - What can we expect?
Christie M. Ballantyne, MD, FNLA
11:45- 12:05 PM
ARS Questions/ Panel Session Q&A
12:05- 12:15 PM
Young Investigator Awards & SWLA Chapter Business Meeting
12:15- 1:15 PM
Lunch in Exhibit Hall
12:20- 1:10 PM
Non-CME Expert Theater
Clinical Lipidology Track
1:15- 1:20 PM
ARS Questions
1:20- 1:30 PM
Evaluating the Roles of PCSK9 and Specific Receptors in Lipoprotein(a) Catabolism
Marlys L. Koschinsky, PhD
1:30- 2:00 PM
Inherited Triglyceride Disorders
Anne C. Goldberg, MD, FNLA
2:00- 2:10 PM
Antisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
Richard Dunbar, MD
2:10- 2:40 PM
Uncommon Dyslipidemias with Common Presentations
James A. Underberg, MD, MS, FNLA
2:40- 3:10 PM
Break in Exhibit Hall
3:10- 3:20 PM
Eicosapentaenoic Acid Reduces Hyperglycemia-induced Small Dense Low-Density Lipoprotein Oxidation In Vitro Differently From Docosahexaenoic Acid
R. Preston Mason, PhD
3:20- 3:50 PM
Lipid Lowering Drug Interactions with Cardiovascular Agents: What you Really need to Know
Barbara S. Wiggins, PharmD, CLS, FNLA
3:50- 4:20 PM
ARS Questions/ Panel Session Q&A
Basic Science Track
1:15- 1:20 PM
ARS Questions
1:20- 1:30 PM
Atherosclerotic Arteries with Cholesterol Crystals Enhance Bacterial Growth: Risk for Plaque Destabilization
Imran Baig, MD
1:30- 2:00
Gut Microbia and Atherothrombotic Heart Disease
Stanley L. Hazen, MD, PhD
2:00- 2:10 PM
Hunninghake Award- Baseline Undertreatment of Adults with Newly Diagnosed Familial Hypercholesterolemia by Genomic Sequencing
Laney K. Jones, PharmD, MPH
2:10- 2:40 PM
New Insights into Omega-3 Fatty Acids and Lipids using Nanotechnology Approaches
R. Preston Mason, MD, MBA
2:40- 3:10 PM
Break in Exhibit Hall
3:10- 3:40 PM
New Frontiers of HDL Research
Anatol Kontush, BSc, PhD
3:40- 4:10 PM
The Role of Hepatic Endothelial Lipase in the Catabolism of VLDL
W. Virgil Brown, MD, FNLA
4:10- 4:30 PM
ARS Questions/ Panel Session Q&A
4:50- 5:40 PM
Non-CME Expert Theater

Saturday, May 21, 2016

7:25- 7:55 AM
Non-CME Mini Symposium- PCSK9 Synthesis Inhibitor for the Treatment of Hypercholesterolemia
8:00- 8:15 AM
MWLA Chapter Business Meetings
8:15- 8:25 AM
Morning Notes and ARS Questions
8:25- 9:25 AM
Pathogenesis and Management of Non-alcoholic Fatty Liver Disease
David E. Cohen, MD, PhD
9:25- 10:00 AM
Break in Exhibit Hall & Poster Hall Q&A Session
10:00- 10:10 AM
NELA Chapter Business Meeting
Session III: Updates in Lipid Therapeutics
10:10- 10:20 AM
ARS Questions
10:20- 10:45 AM
Lipid- Altering Drug Development and Research Update 2016
Harold E. Bays, MD, FNLA
10:45- 11:10 AM
PCSK-9 Antibodies: Lipids and Beyond
Erik S.G. Stroes, MD, PhD
11:10- 11:35 AM
Coronary Artery Calcium Scoring in Young and Low Risk Patients: Impact on lipid lowering pharmacotherapy choices
Michael J. Blaha, MD, MPH
11:35- 11:55 AM
ARS Questions/ Panel Session Q&A
11:55- 12:20 PM
NLA & Foundation Business Meeting
12:20- 1:20 PM
Lunch in Exhibit Hall
12:20- 1:10 PM
Non-CME Expert Theater
Session IV: Update in Lipid Recommendations
1:20- 1:30 PM
ARS Questions
1:30- 1:55 PM
Canadian Perspective of Pediatric Lipid Disorders
Julie St-Pierre, MD, PhD
1:55- 2:20 PM
Updates to the 2016 NLA Annual Summary: Secrets Revealed!
Harold E. Bays, MD, FNLA
2:20- 2:45 PM
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Carl E. Orringer, MD, FNLA
2:45- 3:10 PM
ARS Questions/ Panel Session Q&A
Session V: Familial Hypercholesterolemia
3:10- 3:20 PM
ARS Questions
3:20- 3:45 PM
HoFH a Global Perspective
Marina Cuchel, MD, PhD
3:45- 4:10 PM
FH: Where are we and Where are we Going?
Joshua W. Knowles, MD, PhD, FNLA
4:10- 4:35 PM
Does Genetic Testing in FH Impact Clinical Care? Pros and Cons
Jacques Genest, MD
4:35- 5:00 PM
ARS Questions/ Panel Session Q&A
5:30- 7:00 PM
Honors and Awards Ceremony
7:30- 10:30 PM
Foundation of the National Lipid Association- Night at the Museum Event

Sunday, May 22, 2016

8:00- 8:45 AM
Continental Breakfast
8:45- 9:00 AM
Morning Notes & ARS Questions
9:00- 10:00 AM
Keynote Lecture: Smartphone Applications for Patients' Health and Fitness
John P. Higgins, MD, MBA, MPhil
Session VI: Breakout 1- HIV/AIDS , Dyslipidemia and ASCVD
10:00- 10:05
Activity Overview
10:05- 10:30 AM
HIV and CVD: It is not just about Lipids!
Judith A. Aberg, MD
10:30- 10:55 AM
Risk Stratification for ASCVD in the Patient Living with HIV
Merle Myerson, MD, EdD, FNLA
10:55- 11:20 AM
Residual Risk in the Patient with HIV
Karen E. Aspry, MD, MS, FNLA
11:20- 11:45 AM
The Complex Patient: HIV Plus a Whole Lot Else
Chris T. Longenecker, MD
11:45- 12:00 PM
Panel Session Q&A
Session VI: Breakout 2- Women's Health- Menopause, PCOS, & Pregnancy
10:00- 10:05 AM
Session Overview
10:05- 10:30 AM
ASCVD Risk Assessment in Women: Is it all about her age?
Martha Gulati, MD, MS
10:30- 10:55 AM
Management of FH in Pregnancy: An Art or an Oxymoron?
Pamela B. Morris, MD, FNLA
10:55- 11:20 AM
Selecting the Right Contraception for the Dyslipidemic Woman
Robert A. Wild, MD, MPH, PhD, FNLA
11:20- 11:45 AM
Counseling the Dyslipidemia Post-Menopausal Woman on the Lipid Effects of HRT
Gina Lundberg, MD
11:45- 12:00 PM
Panel Session Q&A
Session VI: Breakout 3- The Obesity Epidemic
10:00- 10:05 AM
Activity Overview
10:05- 10:30 AM
The Obesity Epidemic: What the Clinician Needs to Know
Joyce L. Ross, MSN, CRNP, CLS, FNLA
10:30- 10:55 AM
Current Nutrition Guidelines Incorporating NLA Part 2 Recommendations
Lori A. Alexander, MSHS, RD, CLS, FNLA
10:55- 11:20 AM
Role of Physical Activity in Managing Cardiometabolic Risk
Ralph LaForge, MSc, CLS, FNLA
11:20- 11:45 AM
Strategies for Implementing Behavior Change
Lynne T. Braun, PhD, CNP, CLS, FNLA
11:45- 12:00 PM
Panel Session Q&A

The NLA invites speakers and guests to provide scientific medical opinion, which do not necessarily reflect the policy of the NLA. The schedule and faculty are subject to change.

Faculty


Harold E. Bays, MD, FNLA

Co-Chair
President, Southeast Lipid Association
Medical Director / President
Louisville Metabolic and Atherosclerosis
 Research Center
Louisville, KY
Diplomate, American Board of Clinical Lipidology

James A. Underberg, MD, MS, FNLA

Co-Chair
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for
 Prevention of Cardiovascular Disease
Director, Bellevue Hospital Lipid Clinic
New York, NY
Diplomate, American Board of Clinical Lipidology

Carl E. Orringer, MD, FACC, FNLA*

President,  National Lipid Association
Associate Professor of Medicine
University of Miami
School of Medicine
Miami, FL
Diplomate, American Board of Clinical Lipidology

 

P. Barton Duell, MD

President, Pacific Lipid Association
Director, Lipid Disorder Clinic
Director, Lipid-Atherosclerosis Laboratory
Oregon Health & Science University
Portland, OR

Antonio M. Gotto, Jr., MD, DPhil, FNLA

Dean Emeritus & Co-Chairman
Board of Overseers
Professor
Lewis Thomas University
Weill Cornell Medical College
New York, NY
Diplomate, American Board of Clinical Lipidology

Linda C. Hemphill, MD, FNLA*

President, Northeast Lipid Association
Instructor in Medicine
Harvard Medical School
Assistant Physician in Medicine
Massachusetts General Hospital
Boston, MA
Diplomate, American Board of Clinical Lipidology

Terry A. Jacobson, MD, FNLA

Immediate- Past President, National Lipid Association
Director, Office of Health Promotion and Disease Prevention
Professor of Medicine
Emory University
Atlanta, GA
Diplomate, American Board of Clinical Lipidology

Joseph J. Saseen, PharmD, CLS, FNLA

Professor
Clinical Pharmacy and Family Medicine
University of Colorado Denver
Anschutz Medical Campus
Aurora, CO

Geeta Sikand, MA, RDN, CLS, FNLA, FAND

Associate Clinical Professor of Medicine: Cardiology
University of California Irvine School of Medicine
Director of Nutrition,
University of California Irvine Preventive Cardiology Program
Irvine, CA

Kaye-Eileen Willard, MD

President, Midwest Lipid Association
Chief of Department of Medicine
Medical Director, Chronic Disease Management
Wheaton Franciscan Healthcare, All Saints
Racine, WI
Diplomate, American Board of Clinical Lipidology

Judith A. Aberg, MD

Dr. George Baehr Professor of Medicine
Chief, Division of Infectious Diseases
Icahn School of Medicine at Mount Sinai
New York, NY

Lori A. Alexander, MSHS, RD, CLS, FNLA

Immediate- President, Southeast Lipid Association
St. Johns Center for Clinical Research
Ponte Vedra, FL

Karen E. Aspry, MD, MS, FNLA

Assistant Professor of Medicine (Clinical)
Department of Medicine
The Warren Alpert Medical School
Brown University
East Greenwich, RI
Diplomate, American Board of Clinical Lipidology

Christie M. Ballantyne, MD, FNLA

Professor of Medicine
Chief, Section of Cardiovascular Research
Director, Center for Cardiovascular Disease Prevention
Baylor College of Medicine
Houston, TX
Diplomate, American Board of Clinical Lipidology

Michael J. Blaha, MD, MPH

Director of Clinical Research
Johns Hopkins Ciccarone Center
 for the Prevention of Heart Disease
Cockeysville, MD

W. Virgil Brown, MD, FNLA

Charles Howard Candler Professor Emeritus
Emory University School of Medicine
Atlanta, GA
Diplomate, American Board of Clinical Lipidology

David E. Cohen, MD, PhD

Department of Medicine,
Division of Gastroenterology
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA

Marina Cuchel, MD, PhD

Research Associate Professor
Perelman School of Medicine
University of Pennsylvania Institute for Translational Medicine and Therapeutics
Philadelphia, PA

Sergio Fazio, MD, PhD

William and Sonja Connor Chair of Preventive Cardiology
Professor of Medicine and Physiology & Pharmacology
Director, Center for Preventive Cardiology
The Knight Cardiovascular Institute of OHSU
Portland, OR

Jacques Genest, MD

Professor, Faculty of Medicine
McGill University Research Institute
McGill University Health Center
Montreal, QB, Canada

Anne C. Goldberg, MD, FACP, FNLA

President, Foundation of the NLA
Professor of Medicine
Washington University School of Medicine
St. Louis, MO
Diplomate, American Board of Clinical Lipidology

Martha Gulati, MD, MS

Division Chief of Cardiology
University of Arizona-Phoenix
Phoenix, AZ

John P. Higgins, MD, MBA, MPhil

Associate Professor
The University of Texas
Health Science Center at Houston
Houston, TX

Joshua W. Knowles, MD, PhD

Assistant Professor of Medicine
The Stanford University Medical Center
Stanford, CA
Diplomate, American Board of Clinical Lipidology

Anatol Kontush, BSc, PhD

Senior Research Investigator
Dyslipidemia and Atherosclerosis Research Unit 551
National Institute of Health and Medical Research (INSERM)
Paris, France

Ralph La Forge, MSc, CLS, FNLA

Clinical Exercise Physiologist
Durham, NC

Chris T. Longenecker, MD

Assistant Professor of Medicine
Case Western Reserve University
School of Medicine
Cleveland, OH

Gina Lundberg, MD

Clinical Director Emory Women's Heart Center 
Assistant Professor of Medicine 
Emory University School of Medicine 
Marietta, GA

R. Preston Mason, PhD, MBA

Brigham and Women’s Hospital
Harvard Medical School
Boston, MA
Elucida Research LLC
Beverly, MA

Pamela B. Morris, MD, FNLA

Director, Preventive Cardiology
Co-Director, Women’s Heart Care
Medical University of South Carolina
Charleston, SC
Diplomate, American Board of Clinical Lipidology

Merle Myerson, MD, EdD, FNLA

Division of Applied Physiology
Columbia University
Teachers College New York
New York, NY
Diplomate, American Board of Clinical Lipidology

Børge G. Nordestgaard, MD, DMSc

Professor
Chief Physician
Copenhagen University Hospital
Herlev, Denmark

Muredach P. Reilly, MBBCH, MSCE

Department of Medicine
Columbia University
New York, NY

Joyce L. Ross, MSN, ANP, CLS, CRNP, FPCNA, FNLA

President-Elect, National Lipid Association
Consultative Education Specialist,
  Cardiovascular Risk Intervention
University of Pennsylvania Health System- Retired
Philadelphia, PA

Nathan O. Stitziel, MD, PhD

Assistant Professor of Medicine and Genetics 
Director, Center for Cardiovascular Genetics
Assistant Director, McDonnell Genome Institute
Washington University School of Medicine
St. Louis, MO

Julie St-Pierre, MD, PhD

Professor of Pediatrics
Sherbrooke University, Canada
Chicoutimi, Canada

Erik S.G. Stroes, MD PhD

Department of Vascular Medicine
Academic Medical Center
University of Amsterdam
Amsterdam, the Netherlands

Anne Tybjærg-Hansen, MD, DMSc

Copenhagen University Hospital
Faculty of Health and
Medical Sciences
University of Copenhagen
Copenhagen, Denmark

Barbara S. Wiggins, PharmD, CLS, FNLA

Pharmacy Clinical Specialist- Cardiology
Medical University of South Carolina
Mt Pleasant, SC

Robert A. Wild, MD, MPH, PhD, FNLA

Professor of OB/GYN
Adjunct Professor, Biostatistics and Epidemiology
Department of Family and Preventive Medicine
Adjunct Professor in Epidemiology
University of Pittsburgh
Adjunct Professor of Nutrition
Oklahoma State University
Oklahoma City, OK
Diplomate, American Board of Clinical Lipidology

Featured Sessions


Uncommon Dyslipidemias with Common Presentations

Friday, May 20 • 2:10–2:40 pm

James A. Underberg, MD, MS, FNLA
Treasurer, National Lipid Association
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for Prevention of Cardiovascular Disease
Director, Bellevue Hospital Lipid Clinic
Diplomate, American Board of Clinical Lipidology
New York, NY

 

 

Clinical lipidologists, endocrinologists, cardiologists, and primary care providers continue to see an ever increasing burden of patients with cardiometabolic risk. This phenotype of low HDL-C, high triglycerides, and increased atherogenic lipoproteins is often accompanied by hepatic steatosis and is associated with increased risk for diabetes and atherosclerotic cardiovascular disease. While disorders most often present commonly, they can also be manifestations of more uncommon disorders that can be missed in this “forest” of a known recurring phenotype.

This session will address four disorders that can be confused with metabolic syndrome and hepatic steatosis. We will review the etiology, epidemiology, biology, and treatment options that require distinguishing them from their more common brethren. We will review familial combined hypercholesterolemia, lysosomal acid lipase deficiency, lipodystrophy, and familial chylomicronima syndrome. The advent of new therapeutic interventions, and the need for proper patient counseling and risk assessment, necessitates the need for accurate diagnosis of not only routine disorders, but also the less frequently seen and just as important disorders of lipid and lipoprotein metabolism.


The Role of Hepatic Endothelial Lipase in the Catabolism of VLDL

Friday, May 20 • 3:40–4:10 pm

W. Virgil Brown, MDW. Virgil Brown, MD, FNLA
Charles Howard Candler Professor Emeritus
Emory University School of Medicine
Diplomate, American Board of Clinical Lipidology
Atlanta, GA

 

 


Common forms of hypertriglyceridemia are attributable to reduced clearance of triglyceride rich remnants of VLDL and chylomicrons. Elevated content of apoCIII within the remnants prolongs the residence time of these particles in blood. ApoCIII is thought to inhibit clearance by blocking receptors in the liver that bind to apoB and apoE. However, a very active hepatic triglyceride lipase (HTGL) is in the liver that converts remnants to LDL. Genetic deficiencies and the in vivo inhibition of HTGL increase remnant concentrations. ApoCIII is a powerful inhibitor of both lipoprotein lipase (LPL) and HTGL. Suppression of apoCIII by genetic deficiency or by antisense oligonucleotides, markedly reduces triglyceride levels but maintains apoB concentrations in LDL. Enhanced HTGL activity, not uptake of remnants, is compatible with continuing conversion of remnants into LDL particles. This is a new area for important research in determining the relationship between apoCIII concentrations and arteriosclerosis. 


SATURDAY’S KEYNOTE LECTURE
Pathogenesis and Management of Non-Alcoholic Fatty Liver Disease

Saturday, May 21 • 8:25–9:25 am

David E. Cohen, MDDavid E. Cohen, MD, PhD
Department of Medicine, Division of
Gastroenterology
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA

 

 

 

Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic lipid accumulation in the absence of excess alcohol intake and represents the most common chronic liver disease in the United States. NAFLD is present in approximately 20% of the general population, but in 80% of individuals with the metabolic syndrome. NAFLD is present in 50% of patients with type 2 diabetes and nearly 100% with type 2 diabetes plus obesity. Although the proportion of non-alcoholic steatohepatitis (NASH) is generally low in the overall population of NAFLD patients, it is enriched in diabetics up to nearly 90% of NAFLD cases, with as many as 20% of patients being cirrhotic.

Under normal conditions, steady-state triglyceride concentrations are low in the liver, and this is attributable to a precise balance between uptake of non-esterified fatty acids from the plasma plus de novo lipogenesis, versus triglyceride elimination by fatty acid oxidation and by the secretion of triglyceride-rich very low density lipoproteins (VLDL). Insulin resistance in NAFLD patients leads to hepatic steatosis by multiple mechanisms. These include increased uptake rates of plasma non-esterified fatty acids into the liver, which are attributable to greater release from an expanded mass of adipose tissue in the setting of diminished insulin responsiveness. Hyperinsulinemia and hyperglycemia promote the transcriptional upregulation of genes that promote de novo lipogenesis in the liver. Increases in hepatic lipid accumulation are not offset by fatty acid oxidation or by increased secretion rates of VLDL. 

Because current approaches to the management of NAFLD are very limited, ongoing research efforts are focused on understanding the underlying pathobiology of hepatic steatosis with the anticipation of identifying novel therapeutic targets. 


ACC Expert Consensus Panel Recommendations on Non-Statin Therapy to Reduce ASCVD Risk

Saturday, May 21 • 2:20–2:45 pm

Carl E. Orringer, MD, FACC, FNLA
President, National Lipid Association
Associate Professor of Medicine
University of Miami
School of Medicine
Diplomate, American Board of Clinical Lipidology
Miami, FL

 

 


Clinical lipidologists often confront the important question of when to consider the use of non-statin therapy for ASCVD prevention. In order to provide guidance, the ACC convened an Expert Consensus Decision Pathway writing committee to address current gaps in care for LDL-C lowering to reduce ASCVD risk. The goal was to provide practical guidance for clinicians and patients in situations not covered by the 2013 ACC/AHA Guideline until the next round of guidelines formally reviews scientific evidence, and cardiovascular outcomes trials are completed for new agents being tested for ASCVD risk reduction.

The recommendations are based upon an examination of currently available evidence for net clinical benefit, safety and tolerability, potential for drug-drug interactions, efficacy of additional LDL-C lowering, cost, convenience and medication storage, pill burden, route of administration and patient preferences.

The questions to be addressed are: 1) In what populations should non-statin therapy be considered? 2) In what clinical situations should non-statin therapies be considered, i.e., when is the amount of LDL-C lowering less than anticipated, less than desired, or inadequate, and which treatment options should be considered in patients who are truly statin intolerant? 3) If non-statin therapies are to be added, which agents or therapies should be added and in what order? This presentation will summarize the recommendations of this ACC Expert Panel.

Accreditation


Target Audience

This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses and registered dietitians with an interest in lipid management.

Type of Activity
Live Activity
Knowledge
Application

Educational Objectives
At the conclusion of this activity, registered nurses and nurse practitioners should be able to provide appropriate counsel for patients and their families.

At the conclusion of this activity, all participants should be able to:

Session I: The Impact of Genetics in Lipidology?

  • Apply insight from human population genetics studies to identify novel therapeutic targets for a better understanding for atherosclerotic cardiovascular disease.
  • Describe the current and future technologies available for genetic screen including  how to apply them in clinical practice both for diagnosis and risk assessment
  • Discuss experimental techniques in development for genetic manipulation to target inherited lipid disorders

Keynote I

  • Discuss ApoC3 as both a risk factor for ASCVD and as potential for therapeutic manipulation

Session II: Focus on Lipoprotein(a)

  • Discuss the epidemiology of Lipoprotein(a) (LP(a)) for both thrombosis and ASCVD
  • Discuss the pathophysiology of LP(a) and how this impacts increased risk of ASCVD and thrombosis
  • Discuss the status of current and emerging treatment options targeting LP(a)

Clinical Lipidology Track

  • Critically appraise emerging research and its applications to daily clinical practice
  • Discuss the diagnosis and treatment of genetic hypertriglyceridemia
  • Describe the  approach to diagnosis and therapeutic interventions available to manage uncommon dyslipidemias with common clinical presentations
  • Discuss the clinically relevant drug and non-drug interactions of lipid lowering drugs

Research Track

  • Critically appraise emerging research and its applications to daily clinical practice
  • Describe the impact of the intestinal microbiome on lipid, lipoproteins, and risk for ASCVD
  • Discuss new and emerging treatment for triglyceride biology
  • Discuss new and emerging treatment for HDL biology
  • Discuss evidence regarding hepatic lipase and its impact on ApoC3 and lipoprotein biology

Keynote II

  • Discuss novel concepts in fatty liver disease

Session III- Updates in Lipid Therapeutics

  •  Describe the efficacy, safety, and mechanisms of action of novel lipid-targeted pharmacotherapies
  • Examine the data on safety and efficacy of therapies that target proprotein convertase subtilisin/kexin type 9 (PCSK9)
  • Discuss the clinical application of coronary calcium scores

Session IV- Updates in Lipid Recommendations

  • Discuss Canadian lipid screening and other strategies in children in reducing cardiovascular risk
  • Demonstrate the practical application of the NLA Annual Summary to the clinical evaluation and management of patients with dyslipidemia
  • Discuss current guidelines & recommendations on the diagnosis, management, & treatment of dyslipidemia

Session V- Familial Hypercholesterolemia (FH)- Where do we go from here?

  • Outline European guidelines and recommendations for managing Patients with HoFH
  • Illustrate the importance of universal screening during childhood and cascade lipid screening of family members of known FH patients.
  • Discuss the importance of genetic testing and clinical care for a patient with FH.

Keynote III

  • Discuss the potential role of applications in optimizing lipid management

Session VI- HIV/ AIDS

  • Discuss atherosclerosis in patients with HIV.
  • Differentiate the factors that lead to residual risk in the patient with HIV
  • Apply lipid-lowering treatment strategies in patients with HIV

Session VI- Women’s Health

  • Compare and contrast available risk assessment algorithms (including FRS, ACC/AHA CV Risk Calculator, Reynolds Risk Score, new MESA algorithm) and their accuracy (over- and underestimation) in women
  • Appraise treatment recommendations and evidence for screening, diagnosing and treating FH during pregnancy
  • Describe the impacts of various forms of oral contraception on lipid levels in various types of dyslipidemia.
  • Implement appropriate dyslipidemia management during menopause transition

Session VI- Nutrition & Lifestyle

  • Describe the current guidelines on the diagnosis, management and treatment of obesity
  • Discuss current guidelines & recommendations for nutrition & lifestyle interventions in various populations
  • Review the role of various types of physical activity on dyslipidemia and cardiovascular risk
  • Implement strategies that  improve patient adherence and compliance

 

CME credit provided by the National Lipid Association

Physicians
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Lipid Association designates this live activity for a maximum of 18 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 18 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.

American Academy of Family Physicians
This Live activity, 2016 Annual Scientific Sessions- New Orleans, with a beginning date of 05/19/2016, has been reviewed and is acceptable for up to 13.25 Elective credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


CE credit provided by Postgraduate Institute for Medicine

Pharmacists
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Session I- Universal Activity Number 0809-9999-16-130-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 2.25 contact hour(s) (.225 CEUs) of the Accreditation Council for Pharmacy Education

Keynote I- Universal Activity Number 0809-9999-16-131-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education

Session II – Universal Activity Number 0809-9999-16-132-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (.175 CEUs) of the Accreditation Council for Pharmacy Education

Clinical Breakout– Universal Activity Number 0809-9999-16-133-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.50 contact hour(s) (.250 CEUs) of the Accreditation Council for Pharmacy Education

Research Breakout – Universal Activity Number 0809-9999-16-016-134-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.75 contact hour(s) (.275 CEUs) of the Accreditation Council for Pharmacy Education

Keynote II – Universal Activity Number 0809-9999-16-135-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education

Session III – Universal Activity Number 0809-9999-16-136-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Session IV – Universal Activity Number 0809-9999-16-137-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (.175 CEUs) of the Accreditation Council for Pharmacy Education

Session V – Universal Activity Number 0809-9999-16-138-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (.175 CEUs) of the Accreditation Council for Pharmacy Education

Keynote III – Universal Activity Number 0809-9999-16-139-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education

Session VI HIV/AIDS – Universal Activity Number 0809-9999-16-140-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Session VI Women’s Health – Universal Activity Number 0809-9999-16-141-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Session VI Nutrition & Lifestyle – Universal Activity Number 0809-9999-16-142-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Nursing
This educational activity for 17.2 contact hours is provided by the Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Session I- 2.4 credits; Keynote I- 1.0 credits; Session II- 1.6 credits; Clinical Breakout- 2.5 credits; Research Breakout- 2.7 credits; Keynote II- 1.0 credits; Session III- 1.9 credits; Session IV- 1.8 credits; Session V- 1.8 credits; Keynote III- 1.0 credits; Session VI HIV/AIDS- 2.0 credits; Session VI Women’s Health- 2.0 credits; Session XII Nutrition & Lifestyle- 2.0 credits.  

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Criteria for Success
Statements of credit will be awarded based on the participant's attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/ claimed credit form at www.lipid.org/cme.

For Pharmacists:
Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

Disclosure Statement
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.

Commercial Support
Full notification of commercial support will be provided in the activity syllabus.

Pre-Conference Courses


The Translation of the LDL Receptor: an NLA Core Curriculum Intensive Program is offered as a 1.5-day course prior to the start of the NLA 2016 Scientific Sessions and provides a comprehensive, in-depth indoctrination to advanced lipid science. This masters-level course is designed to address knowledge, competence, and practice gaps in managing residual CVD risk related to high LDL-C and to provide lipid specialists with improved proficiency on the complexities of LDL metabolism, functionality, and targets of therapy. The educational curriculum serves to disseminate current, advanced science on LDL metabolism, functionality, and its atherogenic activity, provide a forum for experts in clinical lipidology to convey rapidly evolving research on LDL-C to clinicians, and assess current therapeutic options and therapies in development that may modify LDL-C.

The NLA’s Masters in Lipidology Course is an intensive 2-day training course offers an in-depth review of the core curriculum in Clinical Lipidology for health care professionals who desire to practice at an advanced level within the field. Learn from leading experts, assess your knowledge of lipid science and advance your personal standard of practice.

The NLA's Lipid Academy provides a comprehensive, in-depth indoctrination to lipid science and is open to all health care professionals interested in developing a core competency in the diagnosis and treatment of dyslipidemia. The interactive Lipid Academy course provides health professionals with the knowledge and tools necessary to work effectively in a lipid practice, and will serve as a preparatory course for the Annual Scientific Forum and other advanced lipid training.

Abstracts


View the posterhall online here: lipid.org/eposters

 

Foundation Event


night at the museum stage  Museum

A Night at the Museum
Saturday, May 21, 2016
7:30-10:30 pm
$165 per person

Join us on the evening of Saturday, May 21 at the National WWII Museum in downtown New Orleans for an eventful evening filled with fun, food, exhibits and a show!

The World War II Museum is the top-rated tourist destination in New Orleans and is considered the #3 museum in the country. Designated by Congress as the official WWII museum of the United States, The National WWII Museum will become the destination for our private event just for attendees and guests of the NLA Annual Scientific Sessions.

The night will kick off with cocktails and private access to one of the key exhibits, exploring the Road to Berlin and will be followed by dinner and drinks.  As guests are enjoying dinner and conversation with friends and colleagues, you will wrap up the night with a live showing of the Johnny Cash Experience, an opportunity to dance and sing along as the songs take you through the late legend’s career.  It will be an eventful evening to say the least, and one not to be missed!

To purchase your tickets, click here.

CME Symposia


CME/CE Dinner Symposium
Thursday, May 19, 2016
6:45-9:15 PM
Celestin D Ballroom, 3rd Floor

Unpeeling the Science and Management of Triglycerides

Despite widespread use of LDL-lowering therapies, cardiovascular (CV) risk remains unacceptably high for many patients with dyslipidemia. While recent sciences has uncovered triglyceride-rich lipoproteins (TRL) as an important casual contributor of CV disease and events, clinicians struggle to optimize its management with the current knowledge base.
This activity features three highly acclaimed faculty who will address the science and management of TRLs in a rigorous yet engaging symposium designed to help clinicians improve their understanding and treatment of TRL-based dyslipidemia.

Sergio Fazio, MD, PhD, FAAP, FASCI
R. Preston Mason, PhD
Michael Miller, MD, FACC, FAHA

Attendance Is Limited!
Complimentary registration for this event must be submitted online at:
http://events.medtelligence.net/May19.html

Hosted by Medtelligence 

Expert Theaters


Friday, May 20th

Praluent ® (alirocumab) Injection: Clinical Advancement for LDL-C Management
Speaker: Michael Davidson MD, FACC, FNLA

9:30-10:20 AM
Celestin B-C
Sponsored by Sanofi

Uncovering Hidden Cardiovascular Risk with the PLAC® Test for Lp-PLA2
Speaker: Anthony Lyssy, DO

9:30-10:20 AM
Celestin A
Sponsored by Diadexus

Identifying Familial Chylomicronemia Syndrome (FCS) Patients In Your Practice
Speakers: Seth Baum, MD, FACC, FAHA, FACPM, FNLA
Michael Miller, MD, FACC, FAHA
Michael Davidson, MD, FACC, FNLA

Click Here for Registration!
http://www.expertfcsinfo.com/

12:20-1:10 PM
Celestin B-C
Sponsored by Akcea Therapeutics

Limitations of Current Cardiovascular Disease Risk Assessment: The Role of Advanced Lipoprotein Testing
Speaker: Peter Alagona, MD

12:20-1:10 PM
Celestin A
Sponsored by Quest Diagnostics

Evolving Cholesterol Landscape
Speaker: Peter Toth, MD, PhD, FNLA 

4:50-5:40 PM
Celestin A
Sponsored by Amgen Inc.

The Critical Role of the Lipidologist in the Diagnosis of Lysosomal Acid Lipase Deficiency (LAL-D)
Speaker: James Maciejko, PhD, FACC

Click Here for Registration!
https://www.cmgroupmeetings.com/nlaexperttheater

4:50-5:40 PM
Celestin B-C
Sponsored by Alexion Pharmaceuticals

Saturday, May 21st

PCSK9 Synthesis Inhibitor for the Treatment of Hypercholesterolemia 
Speaker: David Kallend, MD

7:25 – 7:55 AM
Celestin D
Sponsored by The Medicines Company 

Repatha® (evolocumab): Product Overview
Speaker: Eliot Brinton, MD, FAHA, FNLA

12:20-1:10 PM
Celestin B-C
Sponsored by Amgen, Inc.
 

Honors and Awards Ceremony


The National Lipid Association, in cooperation with the certification bodies of the American Board of Clinical Lipidology (ABCL) and the Accreditation Council for Clinical Lipidology (ACCL) will host its annual Honors and Awards Ceremony on Saturday, May 21 at 5:30 PM. The NLA will present the W. Virgil Brown Distinguished Achievement Award, the Honorary Lifetime Membership Award, and the President's Service Award, as well as induct the 2016 class of Fellows of the NLA. The ABCL and ACCL will recognize the achievements of those who successfully passed the ABCL or Clinical Lipid Specialist (CLS) exams.

Mentor and Mentee Reception


Mentors and Mentees Coming Soon

This information is still being developed by our program developers. Please check back soon for updates to be posted as soon as they are available. Also, check for updates in your email. If you are not currently on our emal blast list and you would like to receive communications from and information about NLA programs, Click Here to sign up.

Mobile App


New in 2016! The National Lipid Association will be providing an app with onsite updates and educational content for attendees. More information coming soon about how to download the app in preparation for the meeting.

Social Media


Stay Connected

Support Recognition

Accreditation Council for Clinical Lipidology (ACCL)
The ACCL establishes, certifies, and maintains the clinical competencies of qualified and experienced healthcare professionals specializing in Clinical Lipidology (non-physician and physician). Two levels of certification offered: Clinical Lipid Specialist (CLS) and Lipid Competency Certificate (LCC).
www.lipidspecialist.org

Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases.
www.aegerion.com

Akcea Therapeutics
Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc., is focused on the development and commercialization of new treatments for patients with serious cardiometabolic lipid disorders.
www.akceatx.com

Alexion Pharmaceuticals
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion’s metabolic franchise includes two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare disorders, Strensiq® (asfotase alfa) to treat patients with hypophosphatasia (HPP) and Kanuma™ (sebelipase alfa) to treat patients with lysosomal acid lipase deficiency (LAL-D).
alexion.com

Amarin Pharma, Inc.
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health.  Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids.  For more information, please visit www.amarincorp.com.

American Board of Clinical Lipidology (ABCL)
The ABCL assesses and validates the specialized knowledge and advanced training required to practice in the dynamic and complex field of Lipidology. The only certification program of its kind available to licensed physicians in the United States or Canada.
www.lipidboard.org

Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
www.amgen.com

Blueprint Genetics
Blueprint Genetics is a genetics company in Helsinki and San Francisco. We are a team of cardiologists, geneticists, bioinformaticians and DNA biologists providing comprehensive and high quality genetic diagnostics with Next-Generation Sequencing.
www.blueprintgenetics.com

Boston Heart Diagnostics
Boston Heart is transforming the treatment of cardiovascular disease by providing healthcare providers and their patients with novel, personalized diagnostics and reports with integrated, customized lifestyle programs.
www.bostonheartdiagnostics.com

Cardiology Today & Healio.com by SLACK Inc.
SLACK Incorporated invites you to visit our booth to pick up your free issue of CARDIOLOGY TODAY – News & Perspective for the Cardiovascular Specialist. Also see Cardiology Today’s Intervention – a practical information resource for interventional cardiologists. To receive important email updates, register at Healio.com/Cardiology.

Carlson Labratories, Inc.
Since 1965, Carlson Laboratories has produced the freshest, purest, award-winning vitamins, minerals, fish oils, and other nutritional supplements.  We continue to remain on the forefront of innovation and are proud to offer an advanced product line with over 250 innovative formulas designed with all of your nutritional needs in mind.”
www.carlsonlabs.com

DiaDexus, Inc.
Diadexus develops and commercializes products to aid in predicting cardiovascular disease risk: PLAC(r) Test ELISA Kit, PLAC(r) Test for Lp-PLA2 Activity, and heart failure biomarkers.
www.diadexus.com

Invitae
Invitae’s mission is to bring genetic information into mainstream medical practice to improve healthcare for everyone. We offer clinically validated, affordable genetic testing for oncology, cardiology, neurology, pediatrics, and more.
www.invitae.com

Kaneka Pharma America LLC
Kaneka’s Liposorber Apheresis System is FDA approved for the acute reduction of LDL cholesterol (70-80%) in patients with Familial Hypercholesterolemia and patients who cannot meet their LDL-C goals despite maximum drug therapy. The Liposorber treatment is reimbursed by government and private insurance, and is used in hospitals, clinics, and physician offices across the country.
www.liposorber.com

Kowa Pharmaceuticals America, Inc.
Kowa Pharmaceuticals America, Inc. delivers value-based solutions to patients by investing in the advancement of cardiometabolic therapeutics. The company's flagship product is LIVALO® (pitavastatin) tablets 1mg, 2mg, 4mg.
www.livalohcp.com

LabCorp
LabCorp provides leading-edge tests and services through a national network of primary clinical and specialized laboratories to support cardiovascular disease prevention, diagnosis and management. Services include traditional and advanced lipids; markers of inflammation, acute ischemia and heart failure; genetic tests for inherited diseases and conditions; genetic counseling and ambulatory electrocardiography.
www.labcorp.com

Lipoprotein(a) Foundation
The mission of the Lipoprotein(a) Foundation is to prevent cardiovascular events due to high Lipoprotein(a) by revealing this inherited risk for cardiovascular disease, empowering patients and saving lives. Our goal is to save lives by increasing awareness, advocating for routine testing, and a specific treatment for high Lipoprotein(a). It is estimated that 1 in 5 Americans have high Lipoprotein(a) and are at risk of premature cardiovascular disease. Based in San Carlos, California, The Lipoprotein(a) Foundation is a nonprofit, 501(c)(3) patient advocacy organization with thousands of members nationwide, including patients and their families, health care providers, advocates and consumers committed to helping us live longer, healthier lives. The Lipoprotein(a) Foundation supports, educates and advocates on behalf of the 63 million Americans living with or at risk of cardiovascular disease due to high Lipoprotein(a). Our programs are made possible by donations, grants and corporate partnerships.
www.lipoproteinafoundation.org

MyGenetx
MyGenetx is changing the way people are diagnosed and treated around the world. We are a CLIA certified molecular laboratory with a national footprint in the areas of cardiology, pharmacogenetics, chronic disease, and corporate wellness. MyGenetx is committed to bringing affordable, accessible, and actionable laboratory testing to everyone. Our research and innovative ideas in genetic testing are at the forefront, allowing us to offer personalized medicine and specialized healthcare options, beyond the traditional standard of care.
www.mygenetx.com

Merck
Today's Merck is working to help the world be well. Through our medicines, vaccines, biologic therapies, and animal products, we work with customers and  operate in more than 140 countries to deliver innovative health solutions.  www.merck.com

Quest Diagnostics
Quest Diagnostics, the world’s leading provider of diagnostic testing, information and services, offers the Cardio IQ Solution—a comprehensive approach to heart health.  Visit 4myheart.com and QuestDiagnostics.com.

ReachMD

ReachMD is an award-winning medical broadcasting company delivering education and information to healthcare professionals nationwide through an on air, online, and mobile distribution network.
www.reachmd.com

Retrophin
Retrophin is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently limited patient options.
www.retrophin.com


Sanofi-Regeneron
Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patients’ needs. Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biologic medicines for serious medical conditions. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies utilizing proprietary technologies.
www.regeneron.com

uniQure
uniQure is a leader in the field of gene therapy. Gene therapy offers the prospect of long-term and potentially curative benefit to patients with genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single therapeutic administration. uniQure is developing a pipeline of adeno-associated virus (AAV)-based gene therapies both internally and through multiple collaborations. The Company develops its gene therapies using an innovative, modular technology platform, including the Company’s proprietary manufacturing process. uniQure is advancing a broad pipeline of innovative gene therapies, initially focused on treatments for rare diseases, but through collaborations and strategic partnership the Company has made the next step towards developing gene therapies targeting chronic and degenerative diseases that affect larger populations.
www.uniqure.com

 

Virtual Exhibit Hall


Virtual Exhibit Hall Coming Soon

This information is still being developed by our program developers. Please check back soon for updates to be posted as soon as they are available. Also, check for updates in your email. If you are not currently on our emal blast list and you would like to receive communications from and information about NLA programs, Click Here to sign up.

Industry Council


Industry Council coming soon...

Media Partners


 

 

 

Hyatt Regency

hotel

Hyatt Regency
601 Loyola Avenue
New Orleans, Louisiana, USA, 70113

Meeting Room Rate: $229/night++
Room Reservation Cut-Off Date: Tuesday, May 3, 2016

Experience the best of the Big Easy at this award-winning hotel. Hyatt Regency New Orleans is located in the heart of downtown. Enjoy spacious guestrooms and suites with city featuring stunning city views and incredible amenities including Bywater Pool, StayFit™ gym, and Le Jardin Spa. Take a ride on the Loyola Avenue Streetcar, which passes directly in front of the hotel, or take a walk to the historic French Quarter, Arts District, Audubon Aquarium of the Americas and the scenic Mississippi Riverfront – all located within one mile of the Hyatt Regency hotel.

For reservations call 1-800-633-7313 and ask for the National Lipid Association room rate.

To make your reservations online, please click here.

Flight Discount:
Book your airfare on Delta and receive up to 5% off of your flight to New Orleans. Book your flight on delta.com and enter NMN4W in the “offer” code box when searching for your flight. Discount applicable for travel to and from New Orleans between May 16–25, 2016. 

 

Local Attractions

new orleansFrench Quarter
French Quarter History consists of over 200 years of characters, chaos, and intrigue. The heart and cultural center of New Orleans is the French Quarter, a must-see for its high energy, rich history, diverse architecture, music, street performers, renowned jazz clubs, lively nightlife and the finest art galleries and restaurants in the city.

 

 

audubon zooAudubon Zoo
Located in historic Uptown New Orleans Audubon Zoo offers an exotic mix of animals from around the globe, engaging educational programs, hands-on animal encounters and lush gardens. Unique natural habitat exhibits—such as the award-winning Louisiana Swamp and Jaguar Jungle—showcase the relationship between people and nature. Audubon Zoo is often ranked among the country’s best for innovation and entertainment value!

 

 

jackson squareJackson Square
Historic Jackson Square, originally known in the 18th century as "Place d'Armes," and later renamed in honor of the Battle of New Orleans hero Andrew Jackson, is a timeless attraction in the heart of the French Quarter of New Orleans. The artists, restaurants, museums, merchants and the square itself make Jackson Square one of the French Quarter's most popular destinations.

 

 

audobon aquariumAudubon Aquarium of the Americas
Located on the Mississippi River adjacent to the French Quarter Audubon Aquarium of the Americas immerses you in an underwater world. The colors of a Caribbean reef come alive in our walk-through tunnel, while our penguins and Southern sea otter enchant you with their antics. Touch a sting ray, feed a parakeet, and marvel at our gigantic sharks, tarpon, and rays in the 400,000 gallon Gulf of Mexico Exhibit. Watch for sea turtles throughout the Aquarium—as coordinator of the Louisiana Marine Mammal and Sea Turtle Rescue Program, we prepare many of them for release to the wild.

 

new orleans museum of artNew Orleans Museum of Art
Today, the museum hosts an impressive permanent collection of almost 40,000 objects. The collection, noted for its extraordinary strengths in French and American art, photography, glass, and African and Japanese works, continues to expand and grow, making NOMA one of the top art museums in the south. The five-acre Sydney and Walda Besthoff Sculpture Garden at NOMA is one of the most important sculpture installations in the United States, with over 60 sculptures situated on a beautifully landscaped site amongst meandering footpaths, reflecting lagoons, Spanish moss-laden 200-year-old live oaks, mature pines, magnolias, camellias, and pedestrian bridges.

 

Late Breakers

Late-Breaking Presentation at NLA 2016 Scientific Sessions

Friday, May 20, 2016

Hyatt Regency Hotel, Room Celestin D

 

7:05–7:25 AM:

Abstract Title: Sebelipase Alfa Improves Atherogenic Measures in Adults and Children with Lysosomal Acid Lipase Deficiency

 

Author Presentation: Don P. Wilson, MD, FNLA

 

7:30 – 7:50 AM:

Abstract Title: Inverse Relationship Between Major Adverse Cardiovascular Events and non-High-Density Lipoprotein Cholesterol and Apolipoprotein B in Phase 3 Trials of Alirocumab

 

Author Presentation: Michael H. Davidson, MD, FACC, FNLA

 

Exhibit in New Orleans

 

 

Interact with several hundred health professionals and lipid experts by supporting the 2016 NLA Scientific Sessions. Sponsorships and exhibits are designed to provide a solid platform to help you stand out and make an impact. As an exhibitor, increase your presence at this meeting by taking advantage of exhibitor-only sponsorship opportunities and showcase all your company has to offer.

We look forward to you having you join us in New Orleans.

Exhibitors Kit

Our official exhibitor services company is GEMS. If you need booth furnishings, electricity, help with shipment or any supplementary materials for your booth please contact Lisa Maag with GEMS:
Lisa Maag
895 Central Florida Parkway
Orlando, FL 32824
Phone: 407-438-5002 ext. 117
lisa@gemsevents.com
www.gemsevents.com

Exhibit and sponsorship packages available. For more information or questions, please contact:
Leia Hutfles, Meeting Coordinator
(p) 904-309-6207 (e) exhibits@lipid.org

Register for 2016 Scientific Sessions

Personal Information

Contact Information

Which meetings or courses would you like to attend?

Must be logged in to click NLA member price
NLA Member
Early Bird Rate

Before 4/8/16
NLA Member
Discounted Rate

After 4/8/16
Non-Member
Rate
Trainee
Rate*
Scientific Sessions**
May 19-22, 2016
$645.00
$795.00
$1150.00
$75.00
Professional Development
Masters in Lipidology Course
May 18-19, 2016
$750.00
$750.00
$1250.00
$395.00
Lipid Academy
May 18-19, 2016
$550.00
$550.00
$950.00
$0.00
LDL Masters Course: Translation of the LDL Receptor: an NLA Core Curriculum Intensive Program
May 18-19, 2016
$295.00
$295.00
$495.00
$0.00
Special Events and Guest Fees
Foundation Event- Night at the Museum
$165 x
Guest Pass- Exhibit Hall
$175 x

*Non-Member Trainees must register with .PDF form.
**Includes one admission badge to Exhibit Hall for all food functions.

Total

$0.00

Payment Information

by Dr. Radut.